CCR2 and Alzheimer disease: Several are pro-inflammatory chemokines, and together, they and their receptors, represented by MCP-1 (chemokines—C-C motif) ligand 2 (CCL2) and its receptor (CCR2), are considered as biomarkers that can be used to evaluate AD progression, since the progression of AD seems to be related to the expression of chemokines [166].